Although artificial intelligence in health has shown great promise, pressure is mounting for regulators around the world to act, as AI tools demonstrate potentially harmful outcomes.
Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications.
By
Integrating robots into a manufacturing system is often prohibitively expensive. A new approach could change that.
HSI Professor Joseph Doyle is interviewed on Freakomomics, M.D. podcast
By
Machine learning is a powerful form of artificial intelligence that is affecting every industry. Here’s what you need to know about its potential and limitations and how it’s being used.
By
In a new book, MIT roboticist Daniela Rus looks at the powers and limitations of robots and how humans can work with them to unlock new capabilities.
By
AI is a tool to get things done. To use it properly and generate value, organizations need the right capabilities — including a good understanding of data.
By
Companies make common data science mistakes. Here’s an expert’s guide to what they are and how to avoid them.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
